End of project evaluation for Unitaid-funded MSF HCV grant

WHO
End of project evaluation for Unitaid-funded MSF HCV grant Request for proposal

Reference: 2018.17
Beneficiary countries or territories: Switzerland
Published on: 31-Aug-2018
Deadline on: 27-Sep-2018 17:00 (GMT 2.00)

Description

Unitaid is seeking for a suitable service provider to carry out an end of project evaluation for the MSF HCV grant (on "Ensuring access to the Hepatitis C (HCV) treatment revolution for HCV/HIV co-infected patients in LMICs") funded by us and we would like to invite you to submit a proposal accordingly.

The tender document with our detailed requirements and the instructions on bid submission are attached in the "Documents" section.

Tender deadlines:

  • Request for Clarification: 13 September 2018 @ 17h00 Geneva time
  • Submission for Intention to Bid: 21 September 2018 @ 17h00 Geneva time
  • Submission of proposal: 27 September 2018 @ 17h00 Geneva time

All queries pertaining to the RFP and the submission of proposal should be addressed in writing to unitaid-proc@who.int.

Thank you for your attention and we look forward to receiving your proposal.

1) Objective of the MSF HCV Grant

Unitaid awarded Médecins Sans Frontières (MSF) a 3-year grant (January 2015-December 2017) for the project "Ensuring access to the Hepatitis C (HCV) treatment revolution for HCV/HIV co-infected patients in LMICs". The project was intended to demonstrate how simplified models of care can treat people co-infected with HIV and HCV in resource-limited settings.

The investment was approved as part of Unitaid’s overall commitment to work with countries to simplify and decentralize the diagnosis and treatment of HCV within the context of HIV co-infection.

Goal: Improve access to HCV diagnosis and treatment in Low & Middle Income Countries (LMICs)

Outcome: Simplified, adapted and affordable HCV care models are developed for adoption in LMICs.

Outputs:

  1. Diagnosis and treatment of HIV co-infected patients implemented in LMICs;
  2. Build a market of affordable HCV products;
  3. Quality-assured DAAs registered in beneficiary countries;
  4. Validation of serology and virologic tests for co-infected patients;
  5. Information on HCV treatment and diagnostic market made available

2. Objectives of the consultancy

The evaluators shall provide Unitaid with an assessment of the programmatic implementation of the project with a particular focus on the project's overall contribution to the public health impact and the part it played in improving access to HCV diagnosis and treatment in project countries captured by the outcome, outputs and activities performed.

For more details, please refer to the tender documents attached.